GALECTIN THERAPEUTICS INC
GALT · Pharmaceutical Preparations · 65.9M shares · +2%/yr ↑ dilution · EDGAR filings ↗
Reference price $3.14 · est. market cap ~$207M — last insider sale, 2026-06-23 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D48Single-asset MASH-cirrhosis developer whose pivotal NAVIGATE trial missed its primary composite endpoint, leaving an uncertain path forward.
Strengths
- Funded through April 2027 with $17.7M cash plus a $10M chairman line of credit
- Encouraging per-protocol/US-subgroup variceal and biomarker signals; clean safety
Risks
- NAVIGATE primary endpoint failed; multiple prior Phase 2s (portal HTN p=1.0, NASH, psoriasis) negative
- Heavy dependence on a single financier (Uihlein); no revenue, recurring going-concern history
Notable findings
- Going concernWe have from time to time faced substantial doubt about our ability to continue as a going concern
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Exec changeRecent 8-K item 5.02 8-K ↗
- Insider sellingInsider selling — 12 open-market sale(s) by 3 insider(s) (cluster of 3 insiders, ~$845,503, last 6mo) Form 4 ↗
- AccumulatingInstitutional holders rose 6→7 QoQ (2025-12-31→2026-03-31)
- Notable holderHeld by 5 notable fund(s): CITADEL ADVISORS LLC, STATE STREET CORP, GOLDMAN SACHS GROUP INC +2 more (as of 2026-03-31)
- New fund positionNotable fund(s) opened this quarter: RENAISSANCE TECHNOLOGIES LLC
Key metrics
Return on equity
24.1%
Return on assets
-157.9%
Current ratio
2.4×
Tangible book value
-$128M
Cash & investments
$18M
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-23 | Jamil Khurram | Sell | 7.6K | $3.14 |
| 2026-06-23 | Jamil Khurram | Option exercise | 7.6K | $1.23 |
| 2026-05-26 | Jamil Khurram | Sell | 568 | $3.10 |
| 2026-05-26 | Jamil Khurram | Option exercise | 568 | $1.23 |
| 2026-02-06 | ELDRED KARY | Buy | 300 | $2.70 |
| 2026-01-16 | Uihlein Richard E | Grant | 13K | $3.04 |
| 2026-01-06 | CALLICUTT JACK W | Sell | 20K | $3.67 |
| 2026-01-06 | LEWIS JOEL | Sell | 38K | $3.58 |
| 2026-01-06 | Jamil Khurram | Sell | 21K | $3.65 |
| 2026-01-05 | CALLICUTT JACK W | Sell | 26K | $3.90 |
| 2026-01-05 | LEWIS JOEL | — | 56K | $3.88 |
| 2026-01-05 | LEWIS JOEL | Sell | 28K | $3.91 |
| 2026-01-05 | Jamil Khurram | Sell | 25K | $3.90 |
| 2026-01-02 | CALLICUTT JACK W | Option exercise | 60K | — |
| 2026-01-02 | LEWIS JOEL | Sell | 19K | $4.20 |
| 2026-01-02 | Jamil Khurram | Option exercise | 60K | — |
| 2026-01-02 | Jamil Khurram | Sell | 13K | $4.20 |
| 2026-01-02 | LEWIS JOEL | Option exercise | 84K | — |
| 2026-01-02 | CALLICUTT JACK W | Sell | 14K | $4.20 |
| 2025-12-31 | Jamil Khurram | Option exercise | 8.1K | $1.23 |
| 2025-12-31 | Jamil Khurram | Sell | 8.1K | $4.07 |
| 2025-12-23 | FREEMAN KEVIN D | Buy | 5.5K | $3.55 |
| 2025-12-23 | FREEMAN KEVIN D | Buy | 5.5K | $3.55 |
| 2025-12-23 | ELDRED KARY | Buy | 700 | $3.73 |
| 2025-12-23 | ELDRED KARY | Buy | 700 | $3.73 |
| 2025-12-23 | FREEMAN KEVIN D | Buy | 5.5K | $3.55 |
| 2025-12-17 | Shlevin Harold H. | Option exercise | 20K | $1.98 |
| 2025-12-17 | LEWIS JOEL | Option exercise | 7.8K | $2.86 |
| 2025-12-17 | LEWIS JOEL | Sell | 7.8K | $7.06 |
| 2025-12-17 | Jamil Khurram | Sell | 4.5K | $7.04 |
| 2025-12-17 | Jamil Khurram | Option exercise | 6.5K | $2.20 |
| 2025-12-17 | Jamil Khurram | Sell | 6.5K | $7.04 |
| 2025-12-17 | Jamil Khurram | Option exercise | 8.5K | $2.50 |
| 2025-12-17 | Jamil Khurram | Sell | 8.5K | $7.04 |
| 2025-12-17 | Shlevin Harold H. | Sell | 20K | $7.04 |
| 2025-12-17 | Shlevin Harold H. | Sell | 4.7K | $7.04 |
| 2025-12-16 | 10X Fund, L.P. | Sell | 31K | $6.66 |
| 2025-12-15 | Shlevin Harold H. | Sell | 8.4K | $6.30 |
| 2025-12-15 | Shlevin Harold H. | Option exercise | 8.4K | $4.16 |
| 2025-12-12 | Shlevin Harold H. | Option exercise | 20K | $4.16 |
| 2025-12-12 | Shlevin Harold H. | Sell | 20K | $6.27 |
| 2025-12-09 | Shlevin Harold H. | Sell | 17K | $6.27 |
| 2025-12-09 | Shlevin Harold H. | Option exercise | 17K | $4.16 |
| 2025-12-08 | Shlevin Harold H. | Option exercise | 35K | $2.86 |
| 2025-12-08 | Shlevin Harold H. | Sell | 35K | $5.95 |
| 2025-12-08 | Shlevin Harold H. | Option exercise | 20K | $2.11 |
| 2025-12-08 | Shlevin Harold H. | Sell | 20K | $5.96 |
| 2025-12-08 | Shlevin Harold H. | Option exercise | 20K | $1.98 |
| 2025-12-08 | Shlevin Harold H. | Sell | 20K | $5.96 |
| 2025-12-08 | Shlevin Harold H. | Option exercise | 25K | $1.72 |
| 2025-12-08 | Shlevin Harold H. | Sell | 25K | $5.95 |
| 2025-12-08 | Shlevin Harold H. | Option exercise | 35K | $2.11 |
| 2025-12-08 | Shlevin Harold H. | Sell | 35K | $6.02 |
| 2025-12-08 | Shlevin Harold H. | Option exercise | 20K | $1.11 |
| 2025-12-08 | Shlevin Harold H. | Sell | 20K | $6.00 |
| 2025-12-08 | Shlevin Harold H. | Sell | 4.0K | $6.00 |
| 2025-12-03 | 10X Fund, L.P. | Sell | 120K | $5.73 |
| 2025-12-03 | 10X Fund, L.P. | Sell | 132K | $5.73 |
| 2025-12-02 | 10X Fund, L.P. | Sell | 30K | $5.47 |
| 2025-12-02 | 10X Fund, L.P. | Sell | 30K | $5.47 |
| 2025-11-24 | 10X Fund, L.P. | Other | 24K | — |
| 2025-11-18 | CALLICUTT JACK W | Sell | 18K | $6.22 |
| 2025-11-18 | CALLICUTT JACK W | Option exercise | 18K | $1.11 |
| 2025-11-18 | LEWIS JOEL | Option exercise | 6.8K | $2.39 |
| 2025-11-18 | LEWIS JOEL | Sell | 6.8K | $6.15 |
| 2025-11-18 | CALLICUTT JACK W | Sell | 28K | $6.22 |
| 2025-11-18 | CALLICUTT JACK W | Option exercise | 28K | $1.98 |
| 2025-11-17 | CALLICUTT JACK W | Sell | 20K | $6.03 |
| 2025-11-17 | LEWIS JOEL | Option exercise | 16K | $2.39 |
| 2025-11-17 | LEWIS JOEL | Sell | 16K | $6.04 |
| 2025-11-17 | CALLICUTT JACK W | Option exercise | 9.6K | $1.98 |
| 2025-11-17 | CALLICUTT JACK W | Sell | 9.6K | $6.03 |
| 2025-11-17 | CALLICUTT JACK W | Option exercise | 20K | $1.11 |
| 2025-11-17 | CALLICUTT JACK W | Option exercise | 2.3K | $1.23 |
| 2025-11-17 | CALLICUTT JACK W | Sell | 2.3K | $6.03 |
| 2025-11-13 | Jamil Khurram | Sell | 22K | $5.47 |
| 2025-11-13 | Jamil Khurram | Option exercise | 42K | $2.20 |
| 2025-11-13 | Jamil Khurram | Sell | 42K | $5.47 |
| 2025-11-13 | Jamil Khurram | Option exercise | 42K | $2.50 |
| 2025-11-13 | Jamil Khurram | Sell | 42K | $5.47 |
| 2025-11-13 | Jamil Khurram | Option exercise | 16K | $1.23 |
| 2025-11-13 | Jamil Khurram | Sell | 16K | $5.47 |
| 2025-11-11 | 10X Fund, L.P. | Sell | 40K | $5.25 |
| 2025-11-10 | LEWIS JOEL | Option exercise | 1.9K | $2.39 |
| 2025-11-10 | LEWIS JOEL | Sell | 1.9K | $6.03 |
| 2025-11-10 | CALLICUTT JACK W | Option exercise | 1.9K | $1.98 |
| 2025-11-10 | CALLICUTT JACK W | Sell | 1.9K | $6.02 |
| 2025-11-10 | CALLICUTT JACK W | Option exercise | 1.7K | $1.11 |
| 2025-11-10 | CALLICUTT JACK W | Sell | 1.7K | $6.03 |
| 2025-11-10 | CALLICUTT JACK W | Option exercise | 1.7K | $1.23 |
| 2025-11-10 | CALLICUTT JACK W | Sell | 1.7K | $6.03 |
| 2025-11-05 | LEWIS JOEL | Option exercise | 200 | $2.39 |
| 2025-11-05 | LEWIS JOEL | Sell | 200 | $6.00 |
| 2025-11-05 | CALLICUTT JACK W | Option exercise | 200 | $1.98 |
| 2025-11-05 | CALLICUTT JACK W | Sell | 200 | $6.00 |
| 2025-11-05 | CALLICUTT JACK W | Option exercise | 200 | $1.11 |
| 2025-11-05 | CALLICUTT JACK W | Sell | 200 | $6.00 |
| 2025-11-05 | CALLICUTT JACK W | Option exercise | 200 | $1.72 |
| 2025-11-05 | CALLICUTT JACK W | Sell | 200 | $6.00 |
| 2025-11-04 | CALLICUTT JACK W | Sell | 9.0K | $6.07 |
| 2025-11-04 | LEWIS JOEL | Option exercise | 14K | $2.39 |
| 2025-11-04 | LEWIS JOEL | Sell | 14K | $6.07 |
| 2025-11-04 | CALLICUTT JACK W | Option exercise | 8.9K | $1.98 |
| 2025-11-04 | CALLICUTT JACK W | Sell | 8.9K | $6.07 |
| 2025-11-04 | CALLICUTT JACK W | Option exercise | 9.0K | $1.11 |
| 2025-11-04 | CALLICUTT JACK W | Option exercise | 11K | $1.72 |
| 2025-11-04 | CALLICUTT JACK W | Sell | 11K | $6.07 |
| 2025-11-03 | CALLICUTT JACK W | Option exercise | 1.2K | $1.72 |
| 2025-11-03 | CALLICUTT JACK W | Sell | 1.2K | $6.01 |
| 2025-11-03 | LEWIS JOEL | Option exercise | 1.3K | $2.39 |
| 2025-11-03 | LEWIS JOEL | Sell | 1.3K | $6.01 |
| 2025-11-03 | CALLICUTT JACK W | Option exercise | 1.3K | $1.98 |
| 2025-11-03 | CALLICUTT JACK W | Sell | 1.3K | $6.01 |
| 2025-11-03 | CALLICUTT JACK W | Option exercise | 1.3K | $1.11 |
| 2025-11-03 | CALLICUTT JACK W | Sell | 1.3K | $6.01 |
| 2025-10-22 | 10X Fund, L.P. | Sell | 30K | $4.94 |
| 2025-10-22 | 10X Fund, L.P. | Sell | 20K | $4.93 |
| 2025-09-12 | CALLICUTT JACK W | Sell | 8.7K | $6.44 |
| 2025-09-12 | LEWIS JOEL | Sell | 14K | $6.36 |
| 2025-09-12 | LEWIS JOEL | Option exercise | 14K | $2.39 |
| 2025-09-12 | CALLICUTT JACK W | Option exercise | 8.7K | $1.37 |
| 2025-07-21 | ELDRED KARY | Buy | 1.0K | $2.92 |
| 2025-07-17 | FREEMAN KEVIN D | Buy | 5.0K | $2.90 |
| 2025-06-06 | CZIRR JAMES C | Option exercise | 70K | $2.11 |
| 2025-06-06 | CZIRR JAMES C | Option exercise | 30K | $2.86 |
| 2025-06-06 | CZIRR JAMES C | Option exercise | 40K | $1.11 |
| 2025-06-06 | CZIRR JAMES C | Option exercise | 31K | $0.89 |
| 2025-06-06 | CZIRR JAMES C | Option exercise | 47K | $2.39 |
| 2025-06-06 | CZIRR JAMES C | Option exercise | 25K | $4.72 |
| 2025-06-06 | CZIRR JAMES C | Option exercise | 40K | $2.11 |
| 2025-06-06 | CZIRR JAMES C | Option exercise | 40K | $1.98 |
| 2025-03-31 | CZIRR JAMES C | Other | 1.0K | $6.00 |
| 2025-03-03 | LEWIS JOEL | Grant | 56K | $1.57 |
| 2025-02-04 | CZIRR JAMES C | Gift | 10K | — |
| 2025-02-03 | CZIRR JAMES C | Gift | 10K | — |
| 2025-01-23 | Uihlein Richard E | Grant | 33K | $1.23 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT04365868 ↗ | Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis | PHASE2/PHASE3 | Terminated | 2025-03-11 |
| NCT04332432 ↗ | A Single-dose, Open-label, Pharmacokinetic Study of Belapectin (GR-MD-02) in Subjects With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment Hepatic Impairment | PHASE1 | Completed | 2022-03-09 |
| NCT02407041 ↗ | An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis Psoriasis | PHASE2 | Completed | 2018-03-01 |
| NCT02462967 ↗ | Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis Hypertension, Portal | PHASE2 | Completed | 2017-10-01 |
| NCT02421094 ↗ | Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis Nonalcoholic Steatohepatitis | PHASE2 | Completed | 2016-09-27 |
| NCT01899859 ↗ | Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis Non-Alcoholic Steatohepatitis (NASH) | PHASE1 | Completed | 2015-02-01 |
| NCT00388700 ↗ | A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer Colorectal Cancer | PHASE2 | Withdrawn | 2009-06-01 |
| NCT00386516 ↗ | Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer Cancer of the Bile Duct, Gallbladder Cancer | PHASE2 | Withdrawn | 2009-06-01 |
| NCT00110721 ↗ | GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer Colorectal Cancer | PHASE2 | Terminated | 2007-06-01 |
| NCT00054977 ↗ | Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors Colorectal Cancer, Lung Cancer | PHASE1 | Completed | 2005-04-01 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-23 | Reg FDExhibits | filing ↗ |
| 2026-05-15 | ResultsExhibits | filing ↗ |
| 2026-03-31 | ResultsExhibits | filing ↗ |
| 2026-03-17 | Exec/director changeExhibits | filing ↗ |
| 2026-01-21 | Exec/director change | filing ↗ |
| 2026-01-12 | Exec/director change | filing ↗ |
| 2025-12-19 | Material agreementExhibits | filing ↗ |
| 2025-12-08 | Shareholder vote | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-23 | 2026-06-23 | 0001140361-26-026031 ↗ |
| 10-Q | 2026-05-15 | 2026-03-31 | 0001140361-26-021495 ↗ |
| 8-K | 2026-05-15 | 2026-05-15 | 0001140361-26-021496 ↗ |
| 8-K | 2026-03-31 | 2026-03-31 | 0001140361-26-012158 ↗ |
| 10-K | 2026-03-31 | 2025-12-31 | 0001140361-26-012155 ↗ |
| 8-K | 2026-03-17 | 2026-03-12 | 0001140361-26-009735 ↗ |
| 8-K | 2026-01-21 | 2026-01-16 | 0001140361-26-001866 ↗ |
| 8-K | 2026-01-12 | 2026-01-10 | 0001140361-26-000994 ↗ |
| 8-K | 2025-12-19 | 2025-12-19 | 0001140361-25-046115 ↗ |
| 8-K | 2025-12-08 | 2025-12-03 | 0001140361-25-044711 ↗ |
| 8-K | 2025-12-03 | 2025-12-03 | 0001140361-25-044148 ↗ |
| 8-K | 2025-11-14 | 2025-11-14 | 0001140361-25-042118 ↗ |